Brief: Ironwood Pharmaceuticals Announces FDA Filing Acceptance Of New Drug Application For Linzess
13/02/2023 12:56
Feb 13 (Reuters) - Ironwood Pharmaceuticals Inc
IRWD.O :
* IRONWOOD PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE
AND
PRIORITY REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR
LINZESS® (LINACLOTIDE) FOR FUNCTIONAL CONSTIPATION IN CHILDREN
AND ADOLESCENTS AGES 6-17 YEARS-OLD
* IRONWOOD PHARMACEUTICALS INC - FDA ASSIGNS 2(ND) QUARTER
2023
TARGET ACTION DATE
Source text for Eikon: ID:nBw4tCfkla
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation